$14.21
-0.45[-3.07%]
At close: May 17
$14.21
0[0.00%]
After Hours: 4:00PM EDT
ALX Oncology Holdings
(NASDAQ:ALXO)ALX Oncology Holdings Stock (NASDAQ:ALXO), Analyst Ratings, Price Targets, Predictions
ALX Oncology Holdings Inc has a consensus price target of $28.67, established from looking at the 29 latest analyst ratings. The last 3 analyst ratings were released from Cantor Fitzgerald, HC Wainwright & Co., and HC Wainwright & Co. on April 12, 2024, April 10, 2024, and March 11, 2024. With an average price target of $13.33 between Cantor Fitzgerald, HC Wainwright & Co., and HC Wainwright & Co., there's an implied -6.17% downside for ALX Oncology Holdings Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
Cantor Fitzgerald
HC Wainwright & Co.
Stifel
Piper Sandler
Jefferies
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for ALX Oncology Holdings
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 04/12/2024 | Buy Now | — | Cantor Fitzgerald | Li Watsek | — | Reiterates | → Overweight | Get Alert |
| 04/10/2024 | Buy Now | 40.75% | HC Wainwright & Co. | Swayampakula Ramakanth | → $20 | Reiterates | Buy → Buy | Get Alert |
| 03/11/2024 | Buy Now | 40.75% | HC Wainwright & Co. | Swayampakula Ramakanth | $17.5 → $20 | Maintains | Buy | Get Alert |
| 03/08/2024 | Buy Now | -1.48% | Stifel | Bradley Canino | $10 → $14 | Downgrade | Buy → Hold | Get Alert |
| 03/08/2024 | Buy Now | 47.78% | Piper Sandler | Christopher Raymond | $11 → $21 | Maintains | Overweight | Get Alert |
| 12/08/2023 | Buy Now | 26.67% | Jefferies | Michael Yee | $8 → $18 | Upgrade | Hold → Buy | Get Alert |
| 11/14/2023 | Buy Now | -29.63% | Stifel | Bradley Canino | $11 → $10 | Maintains | Buy | Get Alert |
| 10/11/2023 | Buy Now | -22.59% | Piper Sandler | Christopher Raymond | $8 → $11 | Maintains | Overweight | Get Alert |
| 10/04/2023 | Buy Now | 90.01% | UBS | Colin Bristow | $29 → $27 | Maintains | Buy | Get Alert |
| 10/04/2023 | Buy Now | 61.86% | Cantor Fitzgerald | Li Watsek | $18 → $23 | Maintains | Overweight | Get Alert |
| 10/03/2023 | Buy Now | 23.15% | HC Wainwright & Co. | Swayampakula Ramakanth | $16 → $17.5 | Reiterates | Buy → Buy | Get Alert |
| 09/12/2023 | Buy Now | 26.67% | Cantor Fitzgerald | Alethia Young | → $18 | Reiterates | Overweight → Overweight | Get Alert |
| 09/07/2023 | Buy Now | 26.67% | Cantor Fitzgerald | Alethia Young | → $18 | Reinstates | Overweight → Overweight | Get Alert |
| 08/14/2023 | Buy Now | 26.67% | Cantor Fitzgerald | Alethia Young | $22 → $18 | Maintains | Overweight | Get Alert |
| 08/11/2023 | Buy Now | 26.67% | Cantor Fitzgerald | Alethia Young | $22 → $18 | Maintains | Overweight | Get Alert |
| 08/11/2023 | Buy Now | -43.7% | Piper Sandler | Christopher Raymond | $48 → $8 | Maintains | Overweight | Get Alert |
| 08/11/2023 | Buy Now | 12.6% | HC Wainwright & Co. | Swayampakula Ramakanth | $30 → $16 | Maintains | Buy | Get Alert |
| 07/24/2023 | Buy Now | 54.82% | Cantor Fitzgerald | Alethia Young | → $22 | Reiterates | Overweight → Overweight | Get Alert |
| 05/12/2023 | Buy Now | 111.12% | HC Wainwright & Co. | Swayampakula Ramakanth | → $30 | Reiterates | Buy → Buy | Get Alert |
| 03/15/2023 | Buy Now | 104.08% | UBS | Colin Bristow | $31 → $29 | Maintains | Buy | Get Alert |
| 03/10/2023 | Buy Now | 139.27% | Credit Suisse | Tiago Fauth | $38 → $34 | Maintains | Outperform | Get Alert |
| 03/10/2023 | Buy Now | 111.12% | HC Wainwright & Co. | Swayampakula Ramakanth | $65 → $30 | Maintains | Buy | Get Alert |
| 11/09/2022 | Buy Now | 357.42% | HC Wainwright & Co. | Swayampakula Ramakanth | $80 → $65 | Maintains | Buy | Get Alert |
| 08/09/2022 | Buy Now | 167.42% | Credit Suisse | Tiago Fauth | $43 → $38 | Maintains | Outperform | Get Alert |
| 06/06/2022 | Buy Now | 12.6% | Stifel | Bradley Canino | $35 → $16 | Maintains | Buy | Get Alert |
| 05/19/2022 | Buy Now | 237.79% | Piper Sandler | Christopher Raymond | $70 → $48 | Maintains | Overweight | Get Alert |
| 03/01/2022 | Buy Now | 153.34% | Stifel | Bradley Canino | $60 → $36 | Maintains | Buy | Get Alert |
| 12/22/2021 | Buy Now | 75.93% | Jefferies | Michael Yee | $65 → $25 | Downgrade | Buy → Hold | Get Alert |
| 09/30/2021 | Buy Now | 645.95% | Stifel | — | — | Initiates | → Buy | Get Alert |
FAQ
What is the target price for ALX Oncology Holdings (ALXO)?
The latest price target for ALX Oncology Holdings (NASDAQ: ALXO) was reported by Cantor Fitzgerald on April 12, 2024. The analyst firm set a price target for $0.00 expecting ALXO to fall to within 12 months (a possible -100.00% downside). 18 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for ALX Oncology Holdings (ALXO)?
The latest analyst rating for ALX Oncology Holdings (NASDAQ: ALXO) was provided by Cantor Fitzgerald, and ALX Oncology Holdings reiterated their overweight rating.
When was the last upgrade for ALX Oncology Holdings (ALXO)?
The last upgrade for ALX Oncology Holdings Inc happened on December 8, 2023 when Jefferies raised their price target to $18. Jefferies previously had a hold for ALX Oncology Holdings Inc.
When was the last downgrade for ALX Oncology Holdings (ALXO)?
The last downgrade for ALX Oncology Holdings Inc happened on March 8, 2024 when Stifel changed their price target from $10 to $14 for ALX Oncology Holdings Inc.
When is the next analyst rating going to be posted or updated for ALX Oncology Holdings (ALXO)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of ALX Oncology Holdings, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for ALX Oncology Holdings was filed on April 12, 2024 so you should expect the next rating to be made available sometime around April 12, 2025.
Is the Analyst Rating ALX Oncology Holdings (ALXO) correct?
While ratings are subjective and will change, the latest ALX Oncology Holdings (ALXO) rating was a reiterated with a price target of $0.00 to $0.00. The current price ALX Oncology Holdings (ALXO) is trading at is $14.21, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.